Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
110.39
+1.12 (1.02%)
May 29, 2026, 4:00 PM EDT - Market closed
Nuvalent Employees
Nuvalent had 234 employees as of March 31, 2026. The number of employees increased by 72 or 44.44% compared to the same quarter last year.
Employees
234
Change
72
Growth
44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,923,393
Market Cap
8.72B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 234 | 72 | 44.44% |
| Dec 31, 2025 | 228 | 86 | 60.56% |
| Sep 30, 2025 | 218 | 91 | 71.65% |
| Jun 30, 2025 | 200 | 85 | 73.91% |
| Mar 31, 2025 | 162 | 56 | 52.83% |
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Sep 30, 2024 | 127 | 38 | 42.70% |
| Jun 30, 2024 | 115 | 37 | 47.44% |
| Mar 31, 2024 | 106 | 36 | 51.43% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Sep 30, 2023 | 89 | 32 | 56.14% |
| Jun 30, 2023 | 78 | 26 | 50.00% |
| Mar 31, 2023 | 70 | 22 | 45.83% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Sep 30, 2022 | 57 | 21 | 58.33% |
| Jun 30, 2022 | 52 | 25 | 92.59% |
| Mar 31, 2022 | 48 | 31 | 182.35% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
NUVL News
- 4 days ago - Nuvalent Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 4 days ago - Nuvalent Slides: Corporate presentation - Filings
- 4 days ago - Nuvalent announces FDA acceptance of neladalkib NDA, Georg Pirmin Meyer as CIO - TheFly
- 4 days ago - Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC - PRNewsWire
- 10 days ago - Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 10 days ago - Bernstein starts Nuvalent with an Outperform, calls it ‘best idea and top pick’ - TheFly
- 10 days ago - Nuvalent initiated with an Outperform at Bernstein - TheFly
- 24 days ago - Nuvalent reports Q1 EPS ($1.39), consensus ($1.31) - TheFly